Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aligos Therapeutics, Inc.

11.44
+1.1611.28%
Post-market: 11.450.0100+0.09%18:54 EDT
Volume:137.74K
Turnover:1.56M
Market Cap:69.95M
PE:-0.89
High:11.76
Open:10.75
Low:10.62
Close:10.28
Loading ...

Aligos Therapeutics trading halted, volatility trading pause

TIPRANKS
·
14 Nov 2024

JMP Securities healthcare analysts hold an analyst/industry conference call

TIPRANKS
·
12 Nov 2024

Aligos Therapeutics trading resumes

TIPRANKS
·
11 Nov 2024

Aligos Therapeutics trading halted, volatility trading pause

TIPRANKS
·
11 Nov 2024

Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations

Simply Wall St.
·
10 Nov 2024

Aligos Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
07 Nov 2024

Promising Prospects for Aligos Therapeutics’ ALG-000184 in Chronic Hepatitis B Treatment

TIPRANKS
·
07 Nov 2024

Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
07 Nov 2024

BRIEF-Aligos Therapeutics files for mixed shelf of up to $400 mln

Reuters
·
07 Nov 2024

Aligos Therapeutics reports Q3 EPS ($3.07), consensus ($2.16)

TIPRANKS
·
07 Nov 2024

Aligos Therapeutics Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing

THOMSON REUTERS
·
07 Nov 2024

Aligos Therapeutics Inc - Cash Balance Provides Sufficient Cash to Fund Planned Operations Through End of 2025

THOMSON REUTERS
·
07 Nov 2024

Aligos Therapeutics Inc - Qtrly Shr Loss $3.07

THOMSON REUTERS
·
07 Nov 2024

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

GlobeNewswire
·
07 Nov 2024

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

GlobeNewswire
·
31 Oct 2024

Aligos Therapeutics Inc expected to post a loss of $2.16 a share - Earnings Preview

Reuters
·
29 Oct 2024